JP2024531437A - （ｒ）－３，４－メチレンジオキシメタンフェタミン及び（ｓ）－３，４－メチレンジオキシメタンフェタミン又は（ｒ）ｎ－メチル－１，３－ベンゾジオキソリルブタンアミン及び（ｓ）ｎ－メチル－１，３－ベンゾジオキソリルブタンアミンの非ラセミ混合物を含む組成物、並びにその使用 - Google Patents

（ｒ）－３，４－メチレンジオキシメタンフェタミン及び（ｓ）－３，４－メチレンジオキシメタンフェタミン又は（ｒ）ｎ－メチル－１，３－ベンゾジオキソリルブタンアミン及び（ｓ）ｎ－メチル－１，３－ベンゾジオキソリルブタンアミンの非ラセミ混合物を含む組成物、並びにその使用 Download PDF

Info

Publication number
JP2024531437A
JP2024531437A JP2024510674A JP2024510674A JP2024531437A JP 2024531437 A JP2024531437 A JP 2024531437A JP 2024510674 A JP2024510674 A JP 2024510674A JP 2024510674 A JP2024510674 A JP 2024510674A JP 2024531437 A JP2024531437 A JP 2024531437A
Authority
JP
Japan
Prior art keywords
disorder
mdma
solvate
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024510674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531437A5 (https=
Inventor
カディシュ、ニコラス
ハウエル、レオナルド
カウル、ハープリート
Original Assignee
ファーマラ バイオテック インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマラ バイオテック インコーポレイテッド filed Critical ファーマラ バイオテック インコーポレイテッド
Publication of JP2024531437A publication Critical patent/JP2024531437A/ja
Publication of JP2024531437A5 publication Critical patent/JP2024531437A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024510674A 2021-08-20 2022-08-22 （ｒ）－３，４－メチレンジオキシメタンフェタミン及び（ｓ）－３，４－メチレンジオキシメタンフェタミン又は（ｒ）ｎ－メチル－１，３－ベンゾジオキソリルブタンアミン及び（ｓ）ｎ－メチル－１，３－ベンゾジオキソリルブタンアミンの非ラセミ混合物を含む組成物、並びにその使用 Pending JP2024531437A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163235460P 2021-08-20 2021-08-20
US63/235,460 2021-08-20
US202263298820P 2022-01-12 2022-01-12
US63/298,820 2022-01-12
PCT/CA2022/051269 WO2023019369A1 (en) 2021-08-20 2022-08-22 Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof

Publications (2)

Publication Number Publication Date
JP2024531437A true JP2024531437A (ja) 2024-08-29
JP2024531437A5 JP2024531437A5 (https=) 2025-09-01

Family

ID=85239329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024510674A Pending JP2024531437A (ja) 2021-08-20 2022-08-22 （ｒ）－３，４－メチレンジオキシメタンフェタミン及び（ｓ）－３，４－メチレンジオキシメタンフェタミン又は（ｒ）ｎ－メチル－１，３－ベンゾジオキソリルブタンアミン及び（ｓ）ｎ－メチル－１，３－ベンゾジオキソリルブタンアミンの非ラセミ混合物を含む組成物、並びにその使用

Country Status (8)

Country Link
US (3) US12053452B2 (https=)
EP (1) EP4387612A4 (https=)
JP (1) JP2024531437A (https=)
KR (1) KR20240061644A (https=)
AU (1) AU2022330718B2 (https=)
CA (1) CA3229363A1 (https=)
IL (1) IL310937A (https=)
WO (1) WO2023019369A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022283967A1 (en) * 2021-06-03 2024-01-18 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
KR20240165982A (ko) * 2022-03-31 2024-11-25 트랜센드 테라퓨틱스 인코퍼레이티드 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022150525A1 (en) * 2021-01-06 2022-07-14 Awakn Life Sciences Mdma in the treatment of alcohol use disorder
WO2022235500A1 (en) 2021-05-03 2022-11-10 Mind Medicine, Inc. Psychedelics for treatment of pain
JP2024517194A (ja) 2021-05-03 2024-04-19 マインド メディシン， インコーポレイテッド サイケデリック薬の用量を漸増する方法
US12611399B2 (en) 2021-05-04 2026-04-28 Definium Therapeutics US, Inc. Movement disorders
WO2022235514A1 (en) 2021-05-04 2022-11-10 Mind Medicine, Inc. Liposome delivery of psychedelics
US20220354822A1 (en) * 2021-05-05 2022-11-10 Mind Medicine, Inc. Mdma enantiomers
WO2022232948A1 (en) * 2021-05-06 2022-11-10 Pharmala Biotech Inc. Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (mdma) and n-methyl-1,3-benzodioxolylbutanamine (mbdb)
WO2022232949A1 (en) * 2021-05-06 2022-11-10 Pharmala Biotech Inc. Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (mdma) and n-methyl-1,3-benzodioxolylbutanamine (mbdb)
AU2022283967A1 (en) 2021-06-03 2024-01-18 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
WO2023056472A1 (en) 2021-09-30 2023-04-06 ATAI Life Sciences AG Enantiomeric ratios of 3,4-methylenedioxymethamphetamine and related metabolites and uses thereof
CA3242786A1 (en) 2022-01-07 2023-07-13 Universitatsspital Basel R-mdma and s-mdma to assist psychotherapy

Also Published As

Publication number Publication date
AU2022330718B2 (en) 2026-02-19
US12053452B2 (en) 2024-08-06
EP4387612A1 (en) 2024-06-26
WO2023019369A1 (en) 2023-02-23
IL310937A (en) 2024-04-01
AU2022330718A1 (en) 2024-03-28
CA3229363A1 (en) 2023-02-23
US20250170095A1 (en) 2025-05-29
EP4387612A4 (en) 2025-07-23
KR20240061644A (ko) 2024-05-08
US20230201159A1 (en) 2023-06-29
US20240335419A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
AU2022330718B2 (en) Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof
US10238643B2 (en) Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
ES2757922T3 (es) Agonistas y composiciones del receptor 5-HT2C y métodos de uso
JP2004513061A (ja) ビュープロピオン代謝物質ならびにその合成方法および使用
US20110034565A1 (en) Psycho-pharmaceuticals
TW202327572A (zh) 用於輔助心理治療的ｒ－ｍｄｍａ和ｓ－ｍｄｍａ
WO2015171547A1 (en) Methods of treating cognitive impairment associated with neurodegenerative disorders
JP2009531431A (ja) 認知障害および他の障害の治療方法
CN102046164B (zh) 烟碱性受体部分激动剂和乙酰胆碱酯酶抑制剂的组合、含有所述组合的药物组合物及其在治疗认知障碍中的用途
US20240252467A1 (en) Treatment of mental illness via administration of buntanetap and analogues thereof
CN118176000A (zh) 包含(r)-和(s)-3,4-亚甲基二氧基甲基苯丙胺或者(r)和(s)n-甲基-1,3-苯并间二氧杂环戊烯基丁胺的非外消旋混合物的组合物及其用途
HK40107764A (zh) 包含(r)-和(s)-3，4-亚甲基二氧基甲基苯丙胺或者(r)和(s)n-甲基-1，3-苯并间二氧杂环戊烯基丁胺的非外消旋混合物的组合物及其用途
US12042478B2 (en) (R)-2-[(2H-1,3-benzodioxol-5-yl)methyl]pyrrolidine and processes for preparation, compositions and uses thereof
US20070225334A1 (en) Methods for treating cognitive and other disorders
WO2023023038A1 (en) Treatment compositions and methods
WO2025111597A1 (en) A treatment for patients with mood disorders using n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine or a pharmaceutically acceptable salt thereof
HK40029163A (en) Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
HK1144784B (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
HK1197916B (en) Use of beta-adrenergic inverse agonists for smoking cessation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250822